Sanofi

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000120578
EUR
83.32
-0.32 (-0.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sanofi stock-summary
stock-summary
Sanofi
Pharmaceuticals & Biotechnology
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
Company Coordinates stock-summary
Company Details
54 rue la Boetie , PARIS None : 75008
stock-summary
Tel: 33 1 5377400033 153 774545
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 6 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Serge Weinberg
Independent Chairman of the Board
Mr. Paul Hudson
Chief Executive Officer, Member of the Executive Committee, Director
Mr. Laurent Attal
Director
Mr. Christophe Babule
Director
Mr. Bernard Charles
Independent Director
Ms. Claudie Haignere
Independent Director
Mr. Patrick Kron
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8,810 Million
(Quarterly Results - Mar 2015)
Net Profit:
1,055 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 105,746 Million ()

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

4.57%

stock-summary
Debt Equity

0.08

stock-summary
Return on Equity

10.62%

stock-summary
Price to Book

1.51